1.	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: CDR0000369699, DFCI-03123, NCT00085397
2.	Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0416, NCT00960752
3.	Phase II Randomized Study of Multipeptide Vaccination Comprising Recombinant MAGE-3.1 Antigen, MART-1 Antigen, gp100 Antigen, and NA17-A2 Peptide Vaccines Emulsified With Montanide ISA-51 With Versus Without Recombinant Interleukin-12 Followed by Daclizumab in Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10-324-B, 10-324-B, 8445, NCT01307618
4.	Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells Phase: Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: Pro00000806, IND # BB-13545, NIH OBA # 0708-874, NCT00672542